1-ethyl-decahydro-quinoline | 91369-86-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉类
• 英文名称: 1-ethyl-decahydro-quinoline
• 英文别名: 1-Aethyl-decahydro-chinolin；N-Ethyldecahydrochinolin；1-ethyl-3,4,4a,5,6,7,8,8a-octahydro-2H-quinoline
• CAS: 91369-86-7
• 化学式: C₁₁H₂₁N
• 分子量: 167.294
• InChiKey: NFRICBBGIFDRGY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  碘乙烷 、 十氢喹啉 在 苯 作用下， 生成 1-ethyl-decahydro-quinoline
  参考文献：
  名称：

  Bis-ammonium Salts. Unsymmetric Derivatives of Decahydroquinoline and of Decahydroisoquinoline

  摘要：

  DOI：

  10.1021/ja01512a053

文献信息

• Cannabinoid receptor ligands and uses thereof
  申请人：Pfizer Inc.

  公开号：US20040214837A1

  公开（公告）日：2004-10-28

  Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein. 1

  本文描述了作为大麻素受体配体的化合物（I）及其在治疗与动物体内大麻素受体介导相关疾病中的用途。
• Benzimidazole and Pyridylimidazole Derivatives
  申请人：Li Guiying

  公开号：US20080227793A1

  公开（公告）日：2008-09-18

  This invention relates to benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds, all of which may be described by of Formula I The invention is particularly related to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABA A receptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Novel processes for preparing compounds of Formula I are disclosed. This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the localization of GABA A receptors in tissue sections.

  本发明涉及苯并咪唑、吡啶咪唑和相关的双环杂芳烃化合物，所有这些化合物都可以用公式I描述。本发明特别涉及与GABAA受体的苯二氮卓位点具有高选择性和高亲和力的这种化合物。本发明还涉及包含这种化合物的制药组合物以及在治疗某些中枢神经系统（CNS）疾病中使用这种化合物的用途。还公开了制备公式I化合物的新方法。本发明还涉及将公式I的苯并咪唑、吡啶咪唑和相关的双环杂芳烃化合物与一个或多个其他CNS药剂联合使用以增强其他CNS药剂的效果。此外，本发明还涉及将这些化合物用作定位组织切片中的GABAA受体的探针。
• CANNABINOID RECEPTOR LIGANDS AND USES THEREOF
  申请人：Griffith A. David

  公开号：US20070275964A1

  公开（公告）日：2007-11-29

  Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.

  本文描述了化学式为(I)的化合物，它们作为大麻素受体配体并在动物中治疗与大麻素受体介导相关的疾病中的用途。
• CXCR4 modulators
  申请人：Thomas D. William

  公开号：US20070275965A1

  公开（公告）日：2007-11-29

  The present invention is directed to novel compounds and pharmaceutical compositions that inhibit the binding of the SDF-1 chemokine to the chemokine receptor CXCR4 and/or the binding of the SDF-1 or I-TAC chemokines to the chemokine receptor CCXCKR2 (CXCR7). These compounds are useful in preventing tumor cell proliferation, tumor formation, metastasis, inflammatory diseases, treatment of HIV infectivity, treatment of stem cell differentiation and mobilization disorders, and ocular disorders.

  本发明涉及新型化合物和制药组合物，可抑制SDF-1趋化因子与趋化因子受体CXCR4的结合，以及SDF-1或I-TAC趋化因子与趋化因子受体CCXCKR2（CXCR7）的结合。这些化合物可用于预防肿瘤细胞增殖、肿瘤形成、转移、炎症性疾病、治疗HIV感染性、治疗干细胞分化和动员障碍以及眼部疾病。
• N-LINKED HETEROCYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS
  申请人：Qiao Jennifer

  公开号：US20100197716A1

  公开（公告）日：2010-08-05

  The present invention provides novel ureas containing N-aryl or N-heteroaryl substituted heterocycles of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, B, D and W are as defined herein. These compounds are selective inhibitors of the human P2Y 1 receptor which can be used as medicaments.

  本发明提供了一种新型尿素，包含式（I）中的N-芳基或N-杂环芳基取代的杂环，或其立体异构体、互变异构体、药学上可接受的盐或溶剂形式，其中变量A、B、D和W如本文所定义。这些化合物是人类P2Y1受体的选择性抑制剂，可用作药物。